Treatment for childhood type 2 diabetes

Clinical Pediatric Endocrinology

Volumn 14, Issue 1, 2005, Pages 1-9

  Urakami, Tatsuhiko ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Childhood type 2 diabetes; Diet and exercise; Insulin; Lifestyle changes; Metformin; Oral hypoglycemic agents

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BARBITURIC ACID DERIVATIVE; BIGUANIDE DERIVATIVE; BOGLIBOSE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLITINIDE DERIVATIVE; INSULIN; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PHENYTOIN; PIOGLITAZONE; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; TROGLITAZONE; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; ALGORITHM; BLOOD TOXICITY; CLINICAL FEATURE; DEHYDRATION; DIET RESTRICTION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; EXERCISE; FAMILY HISTORY; FREQUENCY ANALYSIS; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPOGLYCEMIA; HYPOXEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN TREATMENT; LACTIC ACIDOSIS; LIFESTYLE; LIVER DYSFUNCTION; LIVER FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; SCHOOL; SEX DIFFERENCE; SIDE EFFECT; SKIN MANIFESTATION; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 22744453197     PISSN: 09185739     EISSN: None     Source Type: Journal    
DOI: 10.1297/cpe.14.1     Document Type: Review

References (31)

1. Rosenbloom AL, Joe JR, Young RS, Winter WE. Emerging epidemic of type 2 diabetes in youth. Diabetes Care 1999;22:345-54.
2. American Diabetic Association. Type 2 diabetes in children and adolescents (Consensus Statement). Diabetes Care 2000;25:381-9.
3. Bloomgarden ZT. Type 2 diabetes in the young. The evolving epidemic. Diabetes Care 2004;27:998-1010.
4. Kitagawa T, Owada M, Urakami T, Tajima N. Epidemiology of type 1 (insulin-dependent) and type 2 (non-insulin dependent) diabetes mellitus in Japanese children. Diabetes Res Clin Pract 1994;24 (Suppl.):S7-13.
5. Kitagawa T, Owada M, Urakami T, Yamanouchi K. Increased incidence of non-insulin-dependent diabetes mellitus among Japanese school children correlates with an increased intake of animal protein and fat. Clin Pediatr 1998;37:111-5.
6. Kawamura T, Kadotani S, Kimura K, Nishihara S, Inada H, Ishiki G. The epidemiological study on the prevalence rate of childhood type 2 diabetes in Osaka city of Japan using caputur mark recapture method (abstract). Diabetes 1999;48 (Suppl. 1):A168.
7. Owada M, Nitadori Y, Kitagawa T. Treatment of NIDDM in youth. Clinical Pediatrics 1998;37:117-22.
8. American Diabetic Association. Standards of medical Care for patients with diabetes mellitus. Diabetes Care 2002;25 (Suppl. 1):S33-49.
9. Nathan DM. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 2002;347:1342-9.
10. Genuth S. Insulin use in NIDDM. Diabetes Care 1990;13:1240-6.
11. Rosetti L, Giaccari A, DeFronzo R. Glucose toxicity. Diabetes Care 1990;13:610-30.
12. Tattersall R. Targets of therapy for NIDDM. Diabetes Res Clin Pract 1995;28 (Suppl):49-55.
13. Henry R. Glucose control and insulin resistance in non-insulin diabetes mellitus. Ann Intern Med 1996;124:97-103.
14. Henry R, Gumbinar B. Benefits and limitations of very low-calorie diet therapy in obese NIDDM. Diabetes Care 1992;14:802-23.
15. Chiasson JL, Josse RG, Hunt JA, Plmason C, Rodger NW, Ross SA, et al. The efficacy of acarbose in the treatment of patients with non-insulin dependent diabetes mellitus: a multicenter controlled trial. Ann Intern Med 1994;121:928-35.
16. Josse R. Acarbose for the treatment of type II diabetes: the result of a Canadian multi-center trial. Diabetes Res Clin Pract 1995; 28 (Suppl.):167-72.
17. Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992;15:737-54.
18. Fineberg S, Schneider S. Glipizide versus tolbutamide, an open trial: Effect on insulin secretory patterns and glucose concentrations. Diabetologia 1980;18:45-54.
19. Melander A, Lebovitz H, Faber C. Sulfonylureas:Why, which and how? Diabetes Care 1990;13:18-25.
20. Ferner R, Neil H. Sulfonylureas and hypoglycemia. Br Med J 1998;296:949-50.
21. Jackson J, Besseler R. Clinical pharmacology of sulfonylurea hypoglycemic agents. Drugs 1981;22:211-45.
22. Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and a combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000;23:1660-5.
23. Jones KL, Park JS, Arslanian S, Peterocova VA, Park JS, Tomlinson MJ. Effects of metformin in pediatric patients with type 2 diabetes. a randomized controlled trial. Diabetes Care 2002;25: 89-94.
24. DeFronzo RA, Goodman AM. The Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin dependent diabetes. N Engl J Med 1995;333:541-9.
25. Crofford OB. Metformin. N Engl J Med 1995;333:588-9.
26. Cuse K, DeFronzo RA. Metformin: a review of its metabolic effects: Diabetes Reviews 1998;6:89-131.
27. Marchetti P, Navalesi R. Pharmacokinetic-pharmacodynamic relationships of oral hypoglycemic agents. An update. Clin Pharmacokinet 1989;16:100-28.
28. Neuschwander-Tetri BA, Isley WL, Oki JC, Ramrakhiani S, Quiason SG, Phillips NJ, et al. Troglitazone-induced hepatic failure leading to liver transplantation. A case report. Ann Intern Med 1998;129:38-41.
29. Silverstein JH, Rosenbloom AL. Treatment of type 2 diabetes mellitus in children and adolescents. J Pediatr Endocrinol Metab 2000;13 (Suppl. 6):1403-9.
30. Tattersall R. Traditional pharmacologic management of non-insulin dependent diabetes. Clin Invest Med 1995;18:288-95.
31. Yki-Jarvinen H, Ryysy L, Nikkla K, Tulokas T, Vanamo R, Heikkila M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: randomized controlled trial. Ann Intern Med 1999;130:389-96.